KAVE

None

None

A nitrogen mustard antineoplastic agent. Chemotoxic hormone. An antineoplastic agent consisting of estradiol joined to nornitrogen mustard by a carbamate link, phosphorylated to make it water soluble; used for palliative treatment of metastatic or progressive carcinoma of the prostate. Single agent or combined with taxane for HRPC. FDA approved use on prostate cancer. Pharamcia.

This drug should be coded

None

Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic

This drug should be coded

None

None

An imidazole antifungal agent, has been evaluated in the treatment of advanced prostate cancer, has been designated an orphan product for use in the treatment of nephrotoxicity induced by cyclosporine.

This drug should be coded

None

None

A cell cycle specific chemotherapeutic agent; vinca plant alkaloid; mitotic inhibitor. FDA approved uses in 3rd line breast cancer, choriocarcinoma, palliative in stages III and IV Hodgkin's lymphoma, Kaposi's sarcoma, mycosis fungoides, palliative in non-Hodgkin's histiocytic/lymphocytic lymphoma, and advanced testicular carcinoma.

This drug should be coded